Carcinoma of the Unknown Primary

  • Thomas E. Hutson
  • Ronald M. Bukowski
Part of the Current Clinical Oncology book series (CCO)


The presence of metastatic cancer without evidence of its source is a common clinical entity representing between 3 and 15% of all cancer diagnoses. Patients with cancer of unknown primary (CUP) are heterogenous, having a wide variety of clinical presentations and pathological findings, resulting in diagnostic and treatment dilemmas for both the patient and clinician. Despite having a widely varying prognosis, with optimal treatment, some patients have the potential for long-term survival, whereas others are unlikely to respond to any type of treatment.


Clin Oncol Androgen Deprivation Therapy Peritoneal Carcinomatosis Skeletal Metastasis Spinal Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Holmes FF, Fouts TL. Metastatic cancer of unknown primary site. Cancer 1970; 26:816–820.PubMedCrossRefGoogle Scholar
  2. 2.
    Nystrom JS, Weiner JM, Wolf RM, et al. Identifying the primary site in metastatic cancer of unknown origin. JAMA 1979; 241:381–383.PubMedCrossRefGoogle Scholar
  3. 3.
    Osteen RT, Kopf G, Wilson RE. In pursuit of the unknown primary. Am J Surg 1978; 135:494–498.PubMedCrossRefGoogle Scholar
  4. 4.
    Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57:120–124.PubMedCrossRefGoogle Scholar
  5. 5.
    Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist 1997; 2:142–152.PubMedGoogle Scholar
  6. 6.
    Greco FA, Hainsworth JD. Tumors of unknown origin. CA Cancer J Clin 1992; 42:96–115.PubMedCrossRefGoogle Scholar
  7. 7.
    Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott; 2000:2537–2560.Google Scholar
  8. 8.
    Le Chavalier T, Cvitkovic E, Caille P, et al. Early metastatic cancer of unknown primary origin at presentation: a clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148:2035–2039.CrossRefGoogle Scholar
  9. 9.
    Jordan WE 3rd, Schildt RA. Adenocarcinoma of unknown primary site. The Brooke Army Medical Center experience. Cancer 1985; 55:857–860.PubMedCrossRefGoogle Scholar
  10. 10.
    Maiche AG. Cancer of unknown primary: a retrospective study based on 109 patients. Am J Clin Oncol 1993; 16:26–29.PubMedGoogle Scholar
  11. 11.
    Didolkar MS, Fanous N, Elias EG, Moore RH. Metastatic carcinomas from occult primary tumors: a study of 254 patients. Ann Surg 1977; 186:625–630.PubMedCrossRefGoogle Scholar
  12. 12.
    Abbruzzese JL, Abbruzzese MC, Lenzi R, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12:1272–1280.PubMedGoogle Scholar
  13. 13.
    Casciato DA. Metastasis of unknown origin. In: Haskell CM, Berek JS, eds. Cancer Treatment, 5th ed. Philadelphia, PA: WB Saunders; 2001:1556–1578.Google Scholar
  14. 14.
    Gaber AO, Rice P, Eaton C, et al. Metastatic malignant disease of unknown origin. Am J Surg 1983; 145:493–497.PubMedCrossRefGoogle Scholar
  15. 15.
    Lyman GH, Priesler HD. Carcinoma of unknown primary: natural history and response to therapy. J Med 1978; 9:445–459.PubMedGoogle Scholar
  16. 16.
    Schildt RA, Kennedy PS, Chen TT, et al. Management of patients with metastatic adenocarcinoma of unknown origin. A Southwest Oncology Group study. Cancer Treat Rep 1983; 67:77–79.Google Scholar
  17. 17.
    Krementz ET, Cerise EJ, Foster DS, Morgan LR. Metastasis of undetermined source. Curr Probl Cancer 1979; 4:4–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Markman M. The dilemma of evaluating and treating cancer of unknown primary site. Cleve Clin J Med 1997; 64:73–75.PubMedGoogle Scholar
  19. 19.
    Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329:257–263.PubMedCrossRefGoogle Scholar
  20. 20.
    Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995; 155:2050–2054.PubMedCrossRefGoogle Scholar
  21. 21.
    Gorich J, Beyer-Enke SA, Muller M, et al. The value of computed tomography in the search for an unknown primary tumor. Rofo Fortschr Geb Rontgenstr Nuklearmed 1988; 149:277–279.PubMedCrossRefGoogle Scholar
  22. 22.
    Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82:1160–1166.PubMedCrossRefGoogle Scholar
  23. 23.
    Lenzi R, Hess KR, Abbruzzese MC, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown primary carcinoma? J Clin Oncol 1997; 12:2056–2066.Google Scholar
  24. 24.
    Woods RL, Fox RM, Tattersall MH, Levi JA, Brodie GN. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination chemotherapy regimens. N Engl J Med 1980; 303:87–89.PubMedGoogle Scholar
  25. 25.
    Goldberg RM, Smith FP, Ueno W, et al. Fluorouracil, Adriamycin and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986; 4:395–399.PubMedGoogle Scholar
  26. 26.
    Eagan RT, Thernean TM, Rubin J, et al. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am J Clin Oncol 1987; 10:82–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Fiorre JJ, Kelsen DP, Gralla RJ, et al. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin. Cancer Treat Rep 1985; 69:591–594.Google Scholar
  28. 28.
    Anderson H, Thatcher N, Rankin E, et al. VAD (vincristine, Adriamycin and cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. Eur J Cancer Clin Oncol 1983; 19:49–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912–922.PubMedGoogle Scholar
  30. 30.
    Hainsworth JD, Erland JB, Kalman LA. Carcinoma of unknown primary site: Treatment with one hour paclitaxel, carboplatin and extended schedule etoposide. J Clin Oncol 1997; 15:2385–2394.PubMedGoogle Scholar
  31. 31.
    Briasoulis E, Kaloforous H, Bafalovkos D, et al. Carboplatin plus paclitaxel in unknown primary carcinomaL A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2000; 17:3101–3107.Google Scholar
  32. 32.
    Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11:211–215.PubMedCrossRefGoogle Scholar
  33. 33.
    Greco FA, Erland JB, Patton JF, et al. Carcinoma of unknown primary site: Long-term follow-up after taxane-based chemotherapy (abstract). Proc Am Soc Clin Oncol 2000; 19 597a.Google Scholar
  34. 34.
    Mirra JM. Metastases. In: Mirra, J. M., ed. Bone Tumors: Clinical, Radiologic, and Pathologic Correlations. Philadelphia, PA: Lea and Febiger: 1989:1499.Google Scholar
  35. 35.
    Enkaoua E, Doursounian L, Chatellier G, et al. Vertebral metastasis: a critical appreciation of the preoperative tokuhashi score in a series of 71 cases. Spine 1997; 22:2293–2298.PubMedCrossRefGoogle Scholar
  36. 36.
    Neilan BA. Metastatic spinal cord compression. AFP 1983; 27:191–194.Google Scholar
  37. 37.
    Baron MG, Gandara I de la, Espinosa E, et al. Bone metastasis as the first manifestation of a tumour. Int Orthop 1991; 15:373–376.PubMedCrossRefGoogle Scholar
  38. 38.
    Rougraff BT, Kneisl JS, Simon M. Skeletal metastasis of unknown origin: a prospective study of a diagnostic strategy. J Bone and Joint Surg 1993; 75:1276–1281.Google Scholar
  39. 39.
    Saengnipanthkul S, Jirarattanaphochai K, Rojviroj S, et al. Metastatic adenocarcinoma of the spine. Spine 1992; 17:427–430.PubMedCrossRefGoogle Scholar
  40. 40.
    Stark RJ, Henson RA, Evans SJW. Spinal metastasis: a retrospective survey from a general hospital. Brain 1982; 105:189–213.PubMedCrossRefGoogle Scholar
  41. 41.
    Simon MA, Bartucci EJ. The search for the primary tumor in patients with skeletal metastases of unknown origin. Cancer 1986; 58:1088–1095.PubMedCrossRefGoogle Scholar
  42. 42.
    Harrington KD. The use of methylmetacrylate for vertebral body replacement and anterior stabilization of pathologic fracture dislocation of the spine due to metastatic malignant disease. J Bone Joint Surg 1981; 63:36–47.PubMedGoogle Scholar
  43. 43.
    Steckel RJ, Kagan AR. Diagnostic persistence in working up metastatic cancer with an unknown primary site. Radiology 1980; 134:367–369.PubMedGoogle Scholar
  44. 44.
    Tokuhashi Y, Matsuzaki H, Toriyama S, et al. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 1990; 15:1110–1113.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Thomas E. Hutson
    • 1
  • Ronald M. Bukowski
    • 2
  1. 1.Genitourinary Oncology Program, Texas OncologyBaylor Sammons Cancer CenterDallas
  2. 2.Experimental Therapeutics Program, Taussig Cancer CenterThe Cleveland Clinic FoundationCleveland

Personalised recommendations